![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Adherex and National Cancer Institute to Collaborate
Adherex and National Cancer Institute to Collaborate
March 11, 2005
Adherex Technologies, a biopharmaceutical company with a broad portfolio of oncology products under development, announced that the Drug Development Group of the U.S. National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis has approved a Level III collaboration for the clinical development of the company's lead biotechnology compound ADH-1, also known as Exherin, provided additional preclinical studies be conducted.
Yahoo News (http://biz.yahoo.com/ccn/050311/b7289a3f5a2cf7768e88bb20a72fa9e7_1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct